---
title: "RBC Capital Keeps Their Buy Rating on Damora Therapeutics (DMRA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291271811.md"
description: "RBC Capital analyst Brian Abrahams maintained a Buy rating on Damora Therapeutics (DMRA) with a $40.00 price target. This follows LifeSci Capital's June 22 report, which also issued a Buy rating with a higher $45.00 target. Abrahams is noted as a 5-star analyst covering the Healthcare sector."
datetime: "2026-06-30T11:05:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291271811.md)
  - [en](https://longbridge.com/en/news/291271811.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291271811.md)
generator: "portal-rs"
---

# RBC Capital Keeps Their Buy Rating on Damora Therapeutics (DMRA)

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Damora Therapeutics, with a price target of $40.00.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Abrahams is a 5-star analyst with an average return of 15.8% and a 56.11% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Definium Therapeutics, and Biogen.

In a report released on June 22, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target.

### Related Stocks

- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy](https://longbridge.com/en/news/295521208.md)
- [Wedbush Sticks to Their Buy Rating for Damora Therapeutics (DMRA)](https://longbridge.com/en/news/289928469.md)
- [Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)](https://longbridge.com/en/news/296105482.md)
- [Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/296029142.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**